ONC · NASDAQ
BeOne Medicines (ONC) Stock Price & Fundamentals
BeOne Medicines (ONC) closed at $915.67 on Oct 9, 2026, up 1.04% from the previous close of $906.28.
Share price, past year
1Y +5.07%Monthly closing prices
| Date | Close |
|---|---|
| Oct 9, 2026 | $915.67 |
| Sep 30, 2026 | $900.89 |
| Aug 31, 2026 | $875.74 |
| Jul 31, 2026 | $830.44 |
| Jun 30, 2026 | $871.48 |
| May 29, 2026 | $848.62 |
| Apr 30, 2026 | $837.51 |
| Mar 31, 2026 | $807.69 |
| Feb 27, 2026 | $847.61 |
| Jan 30, 2026 | $858.53 |
| Dec 31, 2025 | $833.66 |
| Nov 28, 2025 | $835.53 |
| Oct 31, 2025 | $853.21 |
Key statistics
- Market cap
- $1.35T
- P/E (TTM)
- 2,081.1
- EPS (TTM)
- $0.44
- Revenue (TTM)
- $6.13B
- Net income (TTM)
- $655.71M
- Shares outstanding
- 1.5B
- Dividend yield
- —
- 52-week range
- $806.55 – $925.92
BeOne Medicines's market cap is $1.35T, based on a share price of $915.67 and 1.5B shares outstanding as of Jun 30, 2026.
Financials
BeOne Medicines reported revenue of $5.34B for fiscal 2025, up 40.23% from fiscal 2024.
BeOne Medicines earned net income of $286.93M in fiscal 2025, a net margin of 5.4%.
Fiscal 2025 revenue was the highest in the 10 years shown.
Annual revenue
| Fiscal year | Revenue | Growth | Net income | Net margin | EPS (diluted) | Free cash flow |
|---|---|---|---|---|---|---|
| FY2025ended Dec 31, 2025 | $5.34B | +40.2% | $286.93M | 5.4% | $0.19 | $941.74M |
| FY2024ended Dec 31, 2024 | $3.81B | +55.0% | −$644.79M | −16.9% | −$0.47 | −$633.29M |
| FY2023ended Dec 31, 2023 | $2.46B | +73.7% | −$881.71M | −35.9% | −$0.65 | −$1.72B |
| FY2022ended Dec 31, 2022 | $1.42B | +20.4% | −$2.00B | −141.5% | −$1.49 | −$1.82B |
| FY2021ended Dec 31, 2021 | $1.18B | +280.8% | −$1.46B | −123.9% | −$1.21 | −$1.56B |
| FY2020ended Dec 31, 2020 | $308.87M | −27.9% | −$1.62B | −526.1% | −$1.50 | −$1.40B |
| FY2019ended Dec 31, 2019 | $428.21M | +116.0% | −$948.63M | −221.5% | −$1.22 | −$839.88M |
| FY2018ended Dec 31, 2018 | $198.22M | −16.9% | −$673.77M | −339.9% | −$0.93 | −$618.00M |
| FY2017ended Dec 31, 2017 | $238.39M | +22,179.2% | −$93.11M | −39.1% | −$0.17 | −$33.62M |
| FY2016ended Dec 31, 2016 | $1.07M | — | −$119.22M | −11,141.8% | −$0.30 | −$113.02M |
| Quarter | Revenue | Net income | EPS (diluted) |
|---|---|---|---|
| Q2 FY2026ended Jun 30, 2026 | $1.71B | $237.01M | $0.16 |
| Q1 FY2026ended Mar 31, 2026 | $1.51B | $227.36M | $0.15 |
| Q4 FY2025ended Dec 31, 2025 | $1.50B | $66.50M | $0.05 |
| Q3 FY2025ended Sep 30, 2025 | $1.41B | $124.84M | $0.08 |
| Q2 FY2025ended Jun 30, 2025 | $1.32B | $94.32M | $0.06 |
| Q1 FY2025ended Mar 31, 2025 | $1.12B | $1.27M | $0.00 |
| Q4 FY2024ended Dec 31, 2024 | $1.13B | −$151.88M | −$0.10 |
| Q3 FY2024ended Sep 30, 2024 | $1.00B | −$121.35M | −$0.09 |
Company profile
- Name
- BeOne Medicines Ltd.
- Ticker
- ONC
- Exchange
- NASDAQ
- Industry (SEC SIC)
- Pharmaceutical Preparations
- Headquarters
- C/O Beone Medicines I Gmbh, Aeschengraben 27, 21st Floor, Basel, 4051
- Fiscal year ends
- December
- SEC CIK
- 0001651308
Recent SEC filings
- Aug 26, 2026
- Aug 5, 2026
- Aug 5, 2026
- Jun 26, 2026
- Jun 11, 2026
- May 15, 2026
- May 6, 2026
- May 6, 2026
Frequently asked questions
What is BeOne Medicines's stock price?
BeOne Medicines (ONC) closed at $915.67 on Oct 9, 2026, up 1.04% from the previous close of $906.28.
What is BeOne Medicines's market cap?
BeOne Medicines's market cap is $1.35T, based on a share price of $915.67 and 1.5B shares outstanding as of Jun 30, 2026.
How much revenue does BeOne Medicines make?
BeOne Medicines reported revenue of $5.34B for fiscal 2025, up 40.23% from fiscal 2024.
What is ONC's P/E ratio?
BeOne Medicines's price-to-earnings ratio is 2,081.1, based on trailing twelve-month diluted EPS of $0.44.
Does BeOne Medicines pay a dividend?
BeOne Medicines's recent filings report no dividends declared over the last four quarters.
Sources and methodology
Fundamentals come from BeOne Medicines Ltd.'s filings with the SEC (EDGAR XBRL company facts). Fourth-quarter figures that companies don't report separately are calculated as the fiscal year minus the first three quarters. Trailing twelve-month (TTM) figures sum the latest four quarters. Prices are generated sample data for development. Last updated Oct 9, 2026. Data sources and disclosures